15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 丙肝论坛 First Vaccine for Viral Hepatitis C Could Become a R ...
查看: 723|回复: 1
go

First Vaccine for Viral Hepatitis C Could Become a Reality [复制链接]

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

1
发表于 2011-4-2 06:05 |只看该作者 |倒序浏览 |打印
http://www.healthnewsdigest.com/news/Research_270/First_Vaccine_for_Viral_Hepatitis_C_Could_Become_a_Reality.shtml
(HealthNewsDigest.com) - BERLIN, April 1, 2011 -- Early data from phase I trials of an HCV vaccine presented today at the International Liver Congress(TM) show encouraging results, with high immunogenicity and good safety profile.(1),(2)

In the first study[1], a therapeutic T-cell vaccine, based on
novel adenoviral vectors was used on a small population of treatment naive
patients with chronic genotype 1 HCV infection. Intra-muscular vaccination
was administered 2 or 14 weeks into a 48-week course of treatment with
Peg-IFNa2a/ribavirin. 50% of vaccinated patients had CD4+ and CD8+ HCV
specific T-cell responses as detected by ELISpot at 2-8 weeks post boost,
showing a strong immunogenicity for the vaccine. Local and systemic adverse
events to vaccination were mild, with no evidence of liver immunopathology
(measured by liver transaminase levels).

The second study[2] looked at the potential for a prophylactic
vaccine based on similar novel adenoviral vectors technology (
replicative-defective human Ad6 and a novel simian AdCh3 vector that encode
1985 amino-acids derived from the NS3-5 region of a genotype-1b strain). 27
healthy volunteers were vaccinated following a double prime, heterologous
boost strategy. The vaccine induced polyfunctional CD4+ and CD8+ T cells
responses which were maintained up to 52 weeks post prime. Overall
vaccination was very well tolerated with mild/moderate local and systemic
reactions and no serious adverse advents.

Professor Heiner Wedemeyer, EASL's Secretary General
commented: "Vaccines are an exciting area of research now with the potential
to add to the range of treatments available for patients with chronic viral
hepatitis. These are early data but results are very encouraging indeed and
as experts, we look forward to more scientific evidence being made available
to support this new technology as a future treatment option as well as
potentially preventing infection."

Previous research and data presented at the International
Liver Congress shows that vaccination with adenoviral vectors induced highly
potent and durable T-cell responses in healthy human and that similar vectors
may prevent chronic infection in animals.(3) This is the first time the
immunogenicity and safety of vaccination was tested on HCV patients and
healthy subjects.

About EASL

EASL is the leading European scientific society involved in promoting
research and education in hepatology. EASL attracts the foremost hepatology
experts and has an impressive track record in promoting research in liver
disease, supporting wider education and promoting changes in European liver
policy.

   [1] Kelly C et al. A therapeutic vaccine for HCV based on novel, rare,
adenoviral vectors. Abstract presented at the International Liver
Congress(TM) 2011. (750)

   [2] Barnes E. Phase I trials of a highly immunogenic and durable T-cell
vaccine for Hepatitis C virus based on novel, rare, adenoviral vectors.
Abstract presented at the International Liver Congress(TM) 2011. (2104)

   [3] Folgori A et al. A T-cell HCV vaccine eliciting effective immunity
against heterologous virus challenge in chimpanzees. Nature Medicine - 12,
190 - 197 (2006)

Rank: 4

现金
171 元 
精华
帖子
195 
注册时间
2011-3-29 
最后登录
2017-11-21 
2
发表于 2011-4-2 19:46 |只看该作者
(HealthNewsDigest.com) - 柏林,2011年4月1日 - 。阶段的早期数据我从一个丙型肝炎病毒疫苗试验发表在国际肝病会议(商标)今天展示了令人鼓舞的成果具有较高的免疫原性和良好的安全性,(1) (2)

在第一项研究[1],一种治疗性T细胞疫苗的基础上,
新型腺病毒载体是用于一个天真的小种群的治疗
1例慢性丙型肝炎病毒感染的基因型。内部肌肉接种
是管理成一个疗程48周的课程有2个或14周
Peg-IFNa2a/ribavirin。接种50%的患者的CD4 +和CD8 + C型肝炎病毒
特异性T细胞的反应,酶联免疫斑点法检测在2-8周后的推动作用,
呈现出强劲的疫苗的免疫原性。局部和全身不良反应
对疫苗的反应是轻度的,没有肝脏免疫病理学证据
(衡量肝转氨酶水平)。

在第二项研究的潜力,看到了很多预防[2]
类似的新技术基于腺病毒载体疫苗(
复制缺陷的人Ad6和一种新的载体,编码猴AdCh3
1985氨基酸来自NS3区- 5基因型- 1B的应变区)。 27
以下健康志愿者接种了双总理,异种
推动策略。该疫苗诱导多作用的CD4 +和CD8 + T细胞
其中维持到52周后的主要反应。总体
接种疫苗是很好的耐受性轻度/中度局部和全身
无严重不良反应和advents。

海纳魏德迈教授,欧洲肝病学会的秘书长
评论说:“疫苗研究的一个令人激动的领域,有可能成为
添加到为病人提供各种治疗慢性病毒性肝炎
肝炎。这些都是早期的数据,但结果是非常令人鼓舞和
作为专家,我们期待着更多的科学证据,提供
以支持未来的治疗选择这一新技术,以及
潜在的预防感染。“

以往的研究和国际提供的数据
肝病会议表明,与腺病毒载体疫苗引起高度
强有力的和持久的T细胞反应在健康人类和类似载体
可以防止动物慢性感染。(3)这是第一次
疫苗免疫原性和安全性进行了测试和对丙型肝炎病毒患者
正常人。

关于欧洲肝病学会

欧洲肝病学会是全球领先的欧洲科学在促进社会参与
肝脏病学研究和教育。欧洲肝病学会吸引首要肝胆病
专家,并在促进肝研究令人印象深刻的记录
疾病,支持更广泛的欧洲教育,促进肝脏的变化
政策。

   [1]凯利C等人。一种新型丙型肝炎治疗性疫苗,稀有的基础上,
腺病毒载体。摘要发表在国际肝病
国会(商标)2011。 (750)

   [2]巴恩斯大肠杆菌第一期高度免疫原性和持久的T -细胞试验
C型肝炎病毒疫苗的基础上新颖,稀有,腺病毒载体。
摘要发表在国际肝病会议(商标)2011。 (2104)

   [3] Folgori A等人。阿T细胞丙型肝炎疫苗的有效免疫引出
对异源病毒的黑猩猩的挑战。自然医学 - 12,
190 - 197(2006)

已有 2 人评分现金 收起 理由
MP4 + 1
StephenW + 4 Great work, many thanks!

总评分: 现金 + 5   查看全部评分

‹ 上一主题|下一主题

肝胆相照论坛

GMT+8, 2024-11-14 10:50 , Processed in 0.013283 second(s), 12 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.